(Updates with stock price movement in the headline and the first paragraph.)

Chemours (CC) shares were up 13% in recent Wednesday trading after the company posted Q2 revenue that topped analysts' estimates.

The company reported Q2 adjusted earnings late Tuesday of $0.58 per diluted share, up from $0.38 a year earlier.

Analysts polled by FactSet expected $0.46.

Sales for the quarter ended June 30 were $1.62 billion, up from $1.55 billion a year earlier.

Analysts polled by FactSet expected $1.57 billion.

For Q3, the company expects consolidated net sales to decrease by 4% to 6% sequentially, with consolidated adjusted EBITDA expected to range between $175 million and $195 million.

The company expects 2025 sales of $5.9 billion to $6 billion. Analysts polled by FactSet are expecting $5.88 billion.

Price: 14.06, Change: +1.64, Percent Change: +13.20